Avrobio (NASDAQ: AVRO)
Avrobio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Avrobio Company Info
Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.
News & Analysis
Here's Why Avrobio Fell as Much as 16.4% Today
The small-cap biopharmaceutical company announced a public stock offering.
Why Seattle Genetics, AVROBIO, and First Majestic Silver Jumped Today
Despite declines in the broader market, good news lifted shares of these companies.
Here's Why Avrobio Rose as Much as 19.9% Today
The gene therapy developer announced higher-than-expected demand for its public stock offering.
Why Crocs, Golden Star Resources, and AVROBIO Jumped Today
Stocks made tiny gains to begin the week.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.